C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial

Siu, Cynthia; Pikalov, Andrei; Tocco, Michael; Loebel, Antony

doi:10.1016/j.bbi.2019.12.010

Cited by 14 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lurasidone has efficacy in bipolar depression in children aged 10-17 years as well as in adults, but long-term preventive data are mixed [29]. It is of interest that in studies of bipolar depression in both children and adults, lurasidone was more effective and had a bigger effect size in those with baseline elevations in the inflammatory marker C-reactive protein (CRP) [30,31].…”

Section: Atypical Antipsychoticsmentioning

confidence: 99%

The Challenges of Children with Bipolar Disorder

Post

Grunze

2021

Medicina

View full text Add to dashboard Cite

Childhood onset bipolar disorder (CO-BD) presents a panoply of difficulties associated with early recognition and treatment. CO-BD is associated with a variety of precursors and comorbidities that have been inadequately studied, so treatment remains obscure. The earlier the onset, the longer is the delay to first treatment, and both early onset and treatment delay are associated with more depressive episodes and a poor prognosis in adulthood. Ultra-rapid and ultradian cycling, consistent with a diagnosis of BP-NOS, are highly prevalent in the youngest children and take long periods of time and complex treatment regimens to achieve euthymia. Lithium and atypical antipsychotics are effective in mania, but treatment of depression remains obscure, with the exception of lurasidone, for children ages 10-17. Treatment of the common comorbid anxiety disorders, oppositional defiant disorders, pathological habits, and substance abuse are all poorly studied and are off-label. Cognitive dysfunction after a first manic hospitalization improves over the next year only on the condition that no further episodes occur. Yet comprehensive expert treatment after an initial manic hospitalization results in many fewer relapses than traditional treatment as usual, emphasizing the need for combined pharmacological, psychosocial, and psycho-educational approaches to this difficult and highly recurrent illness.

show abstract

Section: Atypical Antipsychoticsmentioning

confidence: 99%

The Challenges of Children with Bipolar Disorder

Post

Grunze

2021

Medicina

View full text Add to dashboard Cite

show abstract

“…Three studies [ 60 - 62 ] assessed the effect of lurasidone using the CogState Computerized Cognitive Battery, a well-established assessment battery for cognitive impairment in schizophrenia [ 63 ]. Harvey et al (2015) [ 60 ] performed a 6-month double blind trial of lurasidone compared to quetiapine.…”

Section: Resultsmentioning

confidence: 99%

Cognitive Effects of Lurasidone and Cariprazine: A Mini Systematic Review

Brondino

Olivola

Bassetti

et al. 2023

View full text Add to dashboard Cite

Background: Cognitive deficits are associated with schizophrenia and show a progressive worsening, often being unresponsive to treatment. New antipsychotic molecules acting as antagonist at the serotoninergic 5-hydroxytryptamine receptor 7 (e.g. lurasidone) or partial agonists at dopamine D3 receptor (e.g. cariprazine) could have an impact on cognition in this patient group. Objective: The aim of the systematic review is to explore the efficacy of lurasidone and cariprazine in improving cognition in both animal models and human studies. Methods: The following terms: (lurasidone AND cognit*) OR (cariprazine AND cognit*) were searched in Web of Science from inception to December 2021. We included all studies that assessed changes in cognitive function after treatment with cariprazine or lurasidone. Results: Of 201 selected articles, 36 were included. Twenty-four articles used animal models (rats, mice and marmosets), five evaluating the effects of cariprazine and 19 the effects of lurasidone. Twelve articles were clinical studies (cariprazine n = 2; lurasidone n = 10). In both animal and human studies lurasidone showed a greater efficacy on cognitive performance compared to placebo, quetiap- ine, ziprasidone or treatment-as-usual. Cariprazine was superior to other antipsychotics in improving cognitive functions in both animal and human studies. Conclusion: The cognitive effect of lurasidone could be explained by its potent antagonism at the 5- HT7 receptors combined with partial agonism at 5-HT1A receptors. The pro-cognitive effect of cariprazine is probably explained by its very high affinity for D3 receptors. Head-to-head studies com- paring lurasidone and cariprazine are needed to establish the “first-choice” treatment for cognitive dys- function associated with schizophrenia.

show abstract

“…30 Additionally, CRP is associated with numerous patient and disease characteristics such as BMI, age, leukocyte number, and medications. 29,31 Therefore, our results could have been affected by these potential confounders, which we did not take into consideration.…”

Section: Discussionmentioning

confidence: 96%

Comparison of executive dysfunction, proinflammatory cytokines, and appetite hormones between first-episode and multiple-episode bipolar disorders

et al. 2022

View full text Add to dashboard Cite

Background Evidence has demonstrated associations of bipolar disorder (BD) with cognitive impairment, dysregulated proinflammatory cytokines, and appetite hormones. Aim To compare executive dysfunction, proinflammatory cytokines, and appetite hormones between patients with first-episode and multiple-episode BDs. Methods This cross-sectional study included young adults aged 18 to 39 years who were diagnosed as having type 1 BD in the first or recurrent episode and a group of age-/sex-matched healthy controls. Data regarding patient characteristics, clinical symptoms, cytokines (C-reactive protein [CRP], interleukin-6, and tumor necrosis factor [TNF]-α), appetite hormones (leptin, adiponectin, ghrelin, and insulin), and executive function evaluated using the Wisconsin Card Sorting Test (WCST) were collected. Results A total of 112 participants (38 patients in the multiple-episode BD group, 31 patients in the first-episode BD group, and 43 in the control group) were included. Multivariate analysis revealed that patients in the multiple-episode BD group performed significantly worse in the WCST (P < .05) and had higher levels of ghrelin (P = .002), and lower levels of CRP (P = .040) than those in the first-episode BD group. Patients with BD had significantly higher TNF-α and ghrelin levels compared with the healthy controls. No significant associations of CRP, TNF-α, and ghrelin levels with executive function were observed. Conclusions Profiles in proinflammatory cytokines and appetite hormones as well as executive function significantly differed between patients with first-episode and multiple-episode BDs and controls, which may suggest their potential roles in the clinical stages and pathophysiology of type 1 BD.

show abstract

C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial

Cited by 14 publications

References 38 publications

The Challenges of Children with Bipolar Disorder

The Challenges of Children with Bipolar Disorder

Cognitive Effects of Lurasidone and Cariprazine: A Mini Systematic Review

Comparison of executive dysfunction, proinflammatory cytokines, and appetite hormones between first-episode and multiple-episode bipolar disorders

Contact Info

Product

Resources

About